D-0832-2020 Class II Terminated
FDA drug recall D-0832-2020 was initiated by Graviti Pharmaceuticals Private Limited on Jan 28, 2020 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules: Customer complaint that one 20 mg Atorvastatin Calcium Tablet was present in a bottle labeled as and containing eight-nine Atorvastatin Calcium Tablets, USP 10… The recall status is terminated (terminated Nov 29, 2022). Affected quantity: 29,056 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 12, 2020
- Initiation Date
- Jan 28, 2020
- Termination Date
- Nov 29, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 29,056 bottles
Product description
Atorvastatin Calcium Tablets, USP, 10 mg*, 90-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ 08830-3009 USA; Manufactured By: Graviti Pharmaceuticals Pvt. Ltd., Telangana -502307, INDIA; NDC 70377-027-11.
Reason for recall
Presence of Foreign Tablets/Capsules: Customer complaint that one 20 mg Atorvastatin Calcium Tablet was present in a bottle labeled as and containing eight-nine Atorvastatin Calcium Tablets, USP 10 mg.
Distribution pattern
Nationwide in the USA.
Code information
Lot #: ATA318099C, Exp 12/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0832-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026